Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 4/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30091886 | 0.78 | LMNA (0.39) | CCR4S1PR1KDM4ELMNAHTT | |
| SCHEMBL30369342 | 0.76 | CCR4 (0.46) | CCR4KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL14345363 | 0.73 | MAPK8 (0.43) | LMNAHTTHSD17B10ALDH1A1NPSR1 | |
| SCHEMBL14345462 | 0.72 | CHRNB2 (0.44) | KDM4E | |
| SCHEMBL18081852 | 0.72 | MAPK8 (0.45) | LMNAHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL14301470 | 0.71 | HRH3 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL10409559 | 0.70 | DRD4 (0.62) | KDM4EHTTDRD2DRD4DRD3 | |
| SCHEMBL8154440 | 0.69 | MAPK8 (0.41) | NPSR1 | |
| SCHEMBL16002427 | 0.69 | TSHR (0.42) | HSD17B10ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL2181408 | 0.68 | DRD2 (0.44) | HTTDRD2DRD4DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4129282-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | CCR4 97/4885S1PR1 2886/4885KDM4E 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.